All News

When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.

Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Identifying alterations in tumor genes has enabled medical oncologists to guide patients towards more specific therapies.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

Research shows receipt of medications for chronic conditions was relatively stable in the first 2 years of the pandemic from 2020 to 2021 across racial and ethnic groups.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Investigators previously reported a statistically significant improvement in radiographic progression-free survival in the full intention-to-treat population of adults with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

The primary medication therapies that can help with prophylaxis against HIV include pre-exposure prophylaxis and non-occupational post-exposure prophylaxis.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.

Available pharmacological therapies have shown high efficacy in achieving weight loss.

As patient access, public health advocates flex their muscles to reduce barriers to care, products, will that continue to translate in marketplace?

Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.

The DEA’s decision allows some health care providers to have more leeway in prescribing certain controlled substances.

Navigating the Transition to Year-Round Immunization

Never have there been so many opportunities for non–dispensing pharmacist roles. At the same time, there has never been such a need to save the dispensing environment.